Icon

LEQVIO (nda214012)- (EQ 284MG BASE/1.5ML (EQ 189MG BASE/ML))

INCLISIRAN SODIUM NOVARTIS
EQ 284MG BASE/1.5ML (EQ 189MG BASE/ML)
No No
2036-Aug-25 2026-Dec-22
None None
None No
LEQVIO is a small interfering RNA (siRNA) directed to PCSK9 (proprotein convertase subtilisin kexin type 9) mRNA indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD), who require additional lowering of low- density lipoprotein cholesterol (LDL-C).
0 0 0
Total Other Developers 1
Drugs with Suitability No
EQ 284MG BASE/1.5ML (EQ 189MG BASE/ML) ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.